Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

Authors

Janethe de Oliveira Pena (ORCID: https://orcid.org/0009-0002-8735-4698)
Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
Christine Pausch (ORCID: https://orcid.org/0000-0002-1866-9015)
M. Jootun (ORCID: https://orcid.org/0009-0006-1629-1991)
Gijs van de Wetering (ORCID: https://orcid.org/0009-0001-6498-2950)
Rogier Klok (ORCID: https://orcid.org/0000-0001-6584-4886)
Adnan Alsumali (ORCID: https://orcid.org/0000-0002-5139-3583)
Wenjie Zhang (ORCID: https://orcid.org/0000-0001-8301-2821)
Jestinah Chevure
Dominik Lautsch (ORCID: https://orcid.org/0000-0003-3803-1817)
Eliana C. Martinez (ORCID: https://orcid.org/0000-0002-3335-5997)
Vallerie McLaughlin

Institutions

Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Medizinische Hochschule Hannover (DE)
MSD (UK) Limited (United Kingdom) (GB)
Open Health Systems Laboratory (US)
Michigan Medicine (US)
GWT-TUD (Germany) (DE)
Open University of the Netherlands (NL)

Publication Details

Journal: Advances in Therapy
Published: 2025-06-17
DOI: https://doi.org/10.1007/s12325-025-03241-4
Primary Topic: Pulmonary Hypertension Research and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

Janethe de Oliveira Pena, Marius M. Hoeper, Christine Pausch, M. Jootun et al.

Jun 17, 2025

Advances in Therapy

Pulmonary Hypertension Research and Treatments

article

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

Janethe de Oliveira Pena, Marius M. Hoeper, Christine Pausch, M. Jootun, Gijs van de Wetering, Rogier Klok, Adnan Alsumali, Wenjie Zhang, Jestinah Chevure, Dominik Lautsch, Eliana C. Martinez, Vallerie McLaughlin

June 17, 2025article en

Abstract

No abstract available for this paper.

Advances in TherapyVol. 42(8)

Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Medizinische Hochschule Hannover (DE), MSD (UK) Limited (United Kingdom) (GB), Open Health Systems Laboratory (US), Michigan Medicine (US), GWT-TUD (Germany) (DE), Open University of the Netherlands (NL)

Good health and well-being

Openalex Percentile: Top 77%

Pulmonary Hypertension Research and Treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model — Janethe de Oliveira Pena, Marius M. Hoeper, et al. · Advances in Therapy (2025) | TGRS Research Map | TGRS